https://mindmedicinelaw.com/briefing/spontaneous-neuropathic-pain-mechanisms-and-clinical-implications-20261102-55963The Psychedelic Journalen2026-11-02T22:07:04.052152+00:00Spontaneous Neuropathic Pain: Mechanisms and Clinical Implicationsspontaneous neuropathic pain, pain mechanisms, clinical trial endpoints, psychedelic research, biomarker phenotyping, chronic pain, precision medicine, regulatory policy, pain diagnosticshttps://mindmedicinelaw.com/briefing/epa-proposes-snurs-affecting-psychedelic-chemical-supply-chains-20261102-55802The Psychedelic Journalen2026-11-02T15:06:21.972703+00:00EPA Proposes SNURs Affecting Psychedelic Chemical Supply Chainsepa snur, tsca regulation, psychedelic research chemicals, chemical supply chain, regulatory compliance, premanufacture notice, significant new use, federal register, drug development delayshttps://mindmedicinelaw.com/briefing/psilocybin-s-hidden-order-in-brain-activity-implications-for-research-and-policy-20261101-55846The Psychedelic Journalen2026-11-02T15:06:39.331214+00:00Psilocybin’s 'Hidden Order' in Brain Activity: Implications for Research and Policypsilocybin, hidden order, brain activity, neuroimaging, biomarkers, clinical trial design, regulatory policy, psychedelic research, consciousnesshttps://mindmedicinelaw.com/briefing/rapid-antidepressant-effects-of-psychedelics-clinical-trial-signals-and-policy-i-20261101-55763The Psychedelic Journalen2026-11-01T22:04:56.982336+00:00Rapid Antidepressant Effects of Psychedelics: Clinical Trial Signals and Policy Implicationspsychedelics, depression, rapid antidepressant, clinical trials, regulatory policy, FDA, mechanism of action, mental health, treatment-resistant depression, risk assessmenthttps://mindmedicinelaw.com/briefing/childhood-trauma-linked-to-lower-cb1-receptor-availability-pet-study-insights-20261031-55918The Psychedelic Journalen2026-11-02T22:07:20.229245+00:00Childhood Trauma Linked to Lower CB1 Receptor Availability: PET Study Insightscb1 receptor, childhood trauma, endocannabinoid system, pet imaging, psychedelic therapy, cannabinoid therapy, biomarkers, clinical trial design, neurobiology of traumahttps://mindmedicinelaw.com/briefing/psilocybin-s-anti-inflammatory-effects-in-parkinson-s-implications-for-veteran-a-20261030-55762The Psychedelic Journalen2026-11-01T22:04:45.828031+00:00Psilocybin’s Anti-Inflammatory Effects in Parkinson’s: Implications for Veteran Access and Policypsilocybin, parkinson's disease, anti-inflammatory effects, veteran health policy, clinical trial design, neurodegenerative disorders, fda psychedelic guidance, biomarkers, public health impacthttps://mindmedicinelaw.com/briefing/topical-ketamine-for-oral-mucositis-pain-evidence-and-gaps-in-oncology-supportiv-20261027-55978The Psychedelic Journalen2026-11-02T22:06:27.319413+00:00Topical Ketamine for Oral Mucositis Pain: Evidence and Gaps in Oncology Supportive Caretopical ketamine, oral mucositis, cancer pain management, supportive care, opioid-sparing, clinical trials, oncology, compounding pharmacy, regulatory approval, ketamine safetyhttps://mindmedicinelaw.com/briefing/sex-differences-in-psilocybin-vs-escitalopram-for-depression-2026-bayesian-reana-20261026-55935The Psychedelic Journalen2026-11-02T22:06:49.185755+00:00Sex Differences in Psilocybin vs Escitalopram for Depression: 2026 Bayesian Reanalysispsilocybin, escitalopram, major depressive disorder, sex differences, clinical trial design, bayesian analysis, psychedelic research, hormonal factors, regulatory implicationshttps://mindmedicinelaw.com/briefing/ketamine-extension-vs-buprenorphine-maintenance-clinical-outcomes-compared-20261019-55853The Psychedelic Journalen2026-11-02T15:07:19.756399+00:00Ketamine Extension vs. Buprenorphine Maintenance: Clinical Outcomes Comparedketamine extension, buprenorphine maintenance, substance use disorder, opioid use disorder, clinical trial 2026, policy implications, treatment retention, comparative effectiveness, psychedelic protocols, regulatory pathwayshttps://mindmedicinelaw.com/briefing/buprenorphine-after-ketamine-for-suicidal-ideation-clinical-trial-insights-us-20-20261019-55839The Psychedelic Journalen2026-11-02T15:06:57.410945+00:00Buprenorphine After Ketamine for Suicidal Ideation: Clinical Trial Insights (US, 2026)buprenorphine, ketamine, suicidal ideation, clinical trial, psychedelic research, durability of effect, adjunctive therapy, fda regulatory guidance, opioid modulation